Neoplants

The company began commercial sales in the United States, where GMO consumer regulations are more permissive, but 2026 marks a strategic pivot back to Europe. Neoplants is positioning itself to launch in the UK and select EU markets as the New Genomic Techniques (NGT) framework evolves. This regulatory shift is crucial: it could unlock a path for consumer biotech products to be sold in Europe at scale.

Neoplants is actively engaging with regulators and policymakers to ensure its products meet safety and transparency standards, framing its technology as a climate and public-health benefit rather than a controversial GMO niche. Neoplants is also a serious biotech company under the consumer-friendly brand. It operates a 12,000-square-foot R&D facility in Saint-Ouen, Paris, with capabilities closer to a pharma lab than a greenhouse.

The 2026 R&D pipeline includes plants engineered to capture CO2 at orders-of-magnitude higher rates than typical trees, targeting corporate offices and commercial spaces where sustainability investments must be visible and measurable. That positions Neoplants for a dual-market strategy: consumer air purification today, B2B climate infrastructure tomorrow. The company's ecosystem roots are strong.

The founders, Lionel Mora and Patrick Torbey, met at Entrepreneur First in Paris, and Neoplants was an early resident at Station F. It also benefited from the Wilco healthcare and biotech accelerator. Its investors reflect the blend of deep-tech and consumer focus: True Ventures led the seed, Heartcore Capital and Collaborative Fund support the consumer angle, and angels such as Niklas Zennstrom and Xavier Niel provide strategic visibility.

In 2026, Neoplants represents a "solarpunk" vision of European tech—advanced biology that is both functional and approachable, turning climate and health solutions into products people can live with.